Shares of Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) were up 4.3% on Friday . The stock traded as high as $4.65 and last traded at $4.57, with a volume of 1,633,778 shares trading hands. The stock had previously closed at $4.38.

Several analysts have recently weighed in on SGYP shares. Rodman & Renshaw reissued a “buy” rating and issued a $15.00 price target on shares of Synergy Pharmaceuticals in a research note on Monday, May 23rd. BTIG Research reaffirmed a “buy” rating and set a $11.00 price objective on shares of Synergy Pharmaceuticals in a research report on Monday, May 23rd. Canaccord Genuity reaffirmed a “buy” rating and set a $13.00 price objective on shares of Synergy Pharmaceuticals in a research report on Monday, May 23rd. Zacks Investment Research raised shares of Synergy Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.00 price objective for the company in a research report on Monday, May 16th. Finally, Roth Capital reaffirmed a “buy” rating on shares of Synergy Pharmaceuticals in a research report on Monday, May 9th. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $10.37.

The firm’s market cap is $841.60 million. The stock has a 50 day moving average price of $4.39 and a 200-day moving average price of $3.64.

Synergy Pharmaceuticals (NASDAQ:SGYP) last announced its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by $0.03. Equities research analysts predict that Synergy Pharmaceuticals Inc. will post ($1.03) earnings per share for the current year.

An institutional investor recently raised its position in Synergy Pharmaceuticals stock. Schwab Charles Investment Management Inc. raised its position in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) by 10.7% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 342,232 shares of the biopharmaceutical company’s stock after buying an additional 33,129 shares during the period. Schwab Charles Investment Management Inc. owned about 0.30% of Synergy Pharmaceuticals worth $1,941,000 at the end of the most recent reporting period.

Synergy Pharmaceuticals Inc (Synergy) is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s GI platform includes two lead product candidates: plecanatide and dolcanatide. It is engaged in the discovery, research and development involving uroguanylin analogs for the treatment of functional GI disorders and inflammatory bowel disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.